Abbott Laboratories to buy Alere for $4.4 bln - FT

To learn more about the company, see Here's to Your Health: An Insider's Tour of Abbott Laboratories.

Several other hedge funds have also made changes to their positions in ABT.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on April, 19. Carroll Fincl Associates Inc owns 0% invested in Electronic Arts Inc. Bruderman Asset Management LLC boosted its position in Abbott Laboratories by 0.3% in the third quarter.

During the most recent trading day, the stock's price shifted up +17.82% from its 52-week low and -5.52% lower from its 52-week high. The stock's price fluctuated within the range of $42.39 - $42.96 during previous trading session.

Abbott Laboratories (ABT) stock price fell -1.57 percent over the past one year, while increased 4.12 percent during the past 6 months.

According to sentiments of 13 analysts the company is expected to report revenues of $6.16B for the current quarter.

Stock is now moving with a positive distance from the 200 day simple moving average of approximately 3.09%, and has a solid year to date (YTD) performance of 12.49% which means the stock is constantly adding to its value from the previous fiscal year end price.

Abbott Laboratories (NYSE:ABT) opened at 42.67 on Monday. During the same period in the prior year, the firm posted $0.62 EPS. Abbott Laboratories's revenue for the quarter was up 2.8% on a year-over-year basis.

Abbott Laboratories (NYSE:ABT) has a current MF Rank of 6254. Shareholders of record on Friday, April 14th will be given a dividend of $0.265 per share. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The ex-dividend date is Wednesday, January 11th.

Relative strength index (RSI-14) for Abbott Laboratories (ABT) is at 30.18.

WARNING: This piece of content was originally published by BBNS and is the property of of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & worldwide copyright & trademark law.

A number of analysts recently commented on ABT shares.

08/09/2016 - Abbott Laboratories had its "buy" rating reiterated by analysts at BTIG Research. $2.10M worth of Abbott Laboratories (NYSE:ABT) was bought by WHITE MILES D. On Tuesday, February 28 Contreras Jaime sold $592,157 worth of Abbott Laboratories (NYSE:ABT) or 13,155 shares. Analyst expected twelve month price target of $47.69. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Thursday, January 26th.

Among 15 analysts covering WestRock (NYSE:WRK), 7 have Buy rating, 1 Sell and 7 Hold. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/04/18/l-s-advisors-inc-acquires-new-stake-in-abbott-laboratories-abt-updated.html. The shares were sold at an average price of $45.39, for a total value of $174,796.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Heather L. Mason sold 35,700 shares of the firm's stock in a transaction that occurred on Tuesday, January 31st.

On 2/23/2017 Robert E Funck, VP, sold 25,500 with an average share price of $45.50 per share and the total transaction amounting to $1,160,250.00.

  • Zachary Reyes